I&T International Congress 2023 has ended!

We would like to extend our gratitude to the faculty and all attendees for their participation!

The recordings from the congress are available for free upon site registration, under the ‘Congress 2023’ section.

Welcome to the official website of the “Infections&Transplantation” International Congress.

After two years of unprecedented challenges due to the global pandemic, we are thrilled to announce the new edition of the congress focused on the latest advances in the prevention, diagnosis, and management of infectious complications in transplanted patients. It will be involved an International Faculty of Experts which will share insights and experience on the most pressing challenges facing the transplant community today.

We are delighted to anticipate that the IX Congress “I&T” will take place in the beautiful city of Varese, Italy, from 6th to 8th September, 2023. This event will be a unique opportunity for participants to get connected among peers, engage in interactive sessions and enjoy the picturesque surroundings of Varese.

Join us to an unforgettable learning experience and stay up-to-date on the recent developments in transplantation and infectious diseases. Thank you for visiting our website, we look forward to welcoming you in September!


Paolo Grossi MD, PhD

Paolo Grossi is Professor of Infectious Diseases at the University of Insubria in Varese, Italy. He is also the Director of the Infectious and Tropical Diseases Department of the Ospedale di Circolo and Fondazione Macchi of Varese, Italy, and the Director of the Department of Transplantation.

He is a member of the steering committee of the ESCMID Study Group on infections in Immunocompromised Host (ESGICH).

The main research interest is in the field of infectious complications in transplant recipients. He is author or co-author of more than 200 publications in the field of infectious disease in immunocompromised patients.


From September 6th to 8th, 2023

Palace Grand Hotel Via Luciano Manara 11 – Varese, ITALY



As a registered onsite participant, you will be able to:
Attend the Congress in total safety in compliance with the latest government and health guidelines;
Interact face-to-face with speakers and clinical experts;
Network with colleagues and peers;
Access all online content after the congress.

For all inquiries regarding registration please contact the Organizing Secretariat


All time is expressed in CEST Time (UTC +2)


Solid organ and hematopoietic stem cell transplantation represents one of the most significant advances in medicine in the last 60 years. This field has evolved from the pioneering phase to the current one, which can fully be considered a routine, life-saving, reliable, and cost-effective therapeutic option when compared to alternative treatments for both acute and chronic end-stage organ diseases.

What makes transplantation a daily practice is significantly contributed by progress in the development of new and powerful immunosuppressive drugs that are currently available or in advanced stages of experimentation. However, we are also witnessing an increasing circulation of infectious agents resistant even to the latest antimicrobial drugs, making the issue increasingly complex. Despite significant progress, infectious complications that occur after transplantation continue to be a major cause of morbidity and frequent hospitalization, both in the short and long term.

To discuss the latest advances in the field of transplant infectious diseases, the ninth edition of the International Congress on Infections and Transplantation is taking place in Varese.

In this edition, in addition to the topics related to infections in solid organ transplantation, the characteristics of infections in patients undergoing hematopoietic stem cell transplantation will also be addressed. Patients undergoing hematopoietic stem cell transplantation have an infectious risk sometimes even higher than patients undergoing solid organ transplantation, especially regarding fungal and multi-drug resistant bacterial infections, not to mention the impact of some viral infections, particularly CMV and hepatitis viruses.

HIV infection, which is now chronic thanks to the availability of powerful antiretroviral drugs, is characterized by survival rates similar to those of age-matched individuals without HIV infection. Due to these advances, solid organ and hematopoietic stem cell transplantation in subjects with HIV infection with end-stage organ diseases or oncological and hematological pathologies is now a consolidated reality. The availability of new antiretroviral drugs with reduced toxicity and minimal pharmacological interference between antiretroviral therapies and immunosuppressive drugs opens up new prospects in this field.

The current availability of new antimicrobials with activity against bacterial, fungal, and viral agents makes it extremely important to specify the best prophylaxis and therapy strategies in order to preserve the effectiveness of these new molecules.

In addition, a session will be dedicated to emerging problems caused by both well-known viral agents or tropical origins that represent a new challenge for healthcare professionals.


Thanks to the following companies for their unconditional support:

PIERRE FABRE           ELITECH           PFIZER          ANGELINI          BIOTEST 

GSK           MENARINI           INFECTOPHARM           SHIONOGI




Via Aosta 4/A

20155 – Milano – Italy